This replacement corrects the MRNA August 28 market record with the official $137.99 Nasdaq close, a $4.78 decline, and a 3.35% session move; source context remains separate from the price calculation and does not establish causation.
Correction and verified market record
This article replaces an earlier ChartNova briefing whose terminal daily close was invalid. The replacement uses the complete official Nasdaq historical series retained for this correction. Moderna, Inc. (MRNA) closed August 28 at $137.99, not zero, down $4.78 from the $142.77 August 27 close, a -3.35% move. The corrected record is the only market move used below.
Session anatomy
The August 28 session opened at $137.19, reached $138.80, traded as low as $133.33, and closed at $137.99. The opening gap was -3.91% from the prior close. From the open to the close, MRNA moved +0.58%. The close sat at 85.2% of the session range.
How the correction was validated
The correction is not a manual price substitution. The complete provider response was checked for symbol identity, declared-versus-observed row count, unique strictly ordered session dates, valid positive OHLC values, range consistency, target-date freshness, the August 27 prior close, and the August 28 close. The secondary feed's target-session chart close was null, so that series was rejected; its separately reported regular-market price matched the official $137.99 close. Every chart, calculation, article claim, and image in this replacement derives from the accepted provider series.
Context is not causation
Insider Monkey and Barrons.com add company context, but they do not establish what caused the August 28 move. The reports do not independently confirm one shared catalyst and are not being used to explain the price move. The available source description from Insider Monkey says Moderna (MRNA) & Merck (MRK): What’s Happening With These Two Stocks, published on the target session date; The available source description from Barrons.com says BioNTech Stock Falls on Cancer Vaccine Setback Days After Moderna’s Big Win, published on the target session date. Those records are retained for bounded context only.
Tape and trend context
The full-series calculation shows -4.92% over 5 sessions, +151.71% over 20 sessions, and +181.27% over 60 sessions. August 28 volume was 0.88x the prior 20-session average. The close stood at the 75th percentile of the available 52-week range. These statistics describe the tape; they do not identify a catalyst.
Measured reference levels
This correction intentionally selects no chart pattern. Its technical evidence mode is market-data correction. The analysis still records $60.82 as a measured support reference and $176.66 as a measured resistance or reclaim reference. Those levels come from prior ranges in the same official series and are checkpoints, not predictions, targets, or substitutes for a reproducible pattern signal.
What would change the read
A sustained move above $176.66 would improve the near-term tape, while a close below $60.82 would weaken it. Trading between those references would leave the corrected session as one observation inside a wider range. Fresh company disclosures, regulatory records, or independently corroborated reporting could change the context, but none should be backfilled as the cause of the measured August 28 decline without matching evidence.
Caution
This corrected market-data record is not investment advice, a price target, or a guarantee. Prices can gap through measured levels, data providers can revise historical records, and one completed session does not determine a future trend.